Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis

Liver Transplantation

Volumn 15, Issue 1, 2009, Pages 37-48

  Briceño, Javier ^a   Ciria, Ruben ^a   Pleguezuelo, María ^a   de la Mata, Manuel ^a   Muntané, Jordi ^a   Naranjo, Álvaro ^a   Sánchez Hidalgo, Juan ^a   Marchal, Trinidad ^a   Rufián, Sebastián ^a   López Ciliero, Pedro ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; COLD ISCHEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER PRESERVATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; RECURRENT INFECTION; REPERFUSION INJURY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; BIOPSY; CHILD; FATTY LIVER; FEMALE; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 61749096243     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21566     Document Type: Article

References (66)

1. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
2. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:41-46.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-2441.
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538.
5. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades. A single-center experience. Ann Surg 2005;241:905-918.
6. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-833.
7. Gane E, Portmann B, Naoumov N, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820.
8. Feray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing the outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
9. Böker KH, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25: 203-210.
10. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
11. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
12. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
13. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
14. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006;81:7-14.
15. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcome in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003;9:339-347.
16. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JY, Simmonds P, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996;24: 1041-1046.
17. Sanchez-Bueno F, Ortiz ML, Bermejo J, Miras M, Pons JA, Ramirez P, et al. Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation. Transpl Immunol 2006;17:47-50.
18. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis c virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;28:756-763.
19. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8(suppl 1): S19-S27.
20. Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS Jr, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007;13:122-129.
21. Garcia-Retortillo M, Forns X, Llovet J, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707.
22. Sheiner PA, Schluger LK, Emre S, Thung SN, Lau JY, Guy SR, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997;3:130-136.
23. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996;23: 971-976.
24. Briceno J, Marchal T, Padillo J, Solórzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 2002;74:522-526.
25. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma: validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911-918.
26. Adinolfi L, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
27. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651-663.
28. Urena MA, Moreno Gonzalez E, Romero CJ, Ruiz-Delgado FC, Moreno Sanz C. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenterology 1999;46:1164-1173.
29. Kakizoe S, Yanaga K, Starzl TE, Demetris J. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology 1990;11:932-941.
30. Clavien PA, Harvey PRC, Strasberg SM. Preservation and reperfusion injuries in liver allografts. Transplantation 1992;53:957-978.
31. Kalayoglu M, Sollinger HW, Stratta RJ, D'Alessandro AM, Hoffmann RM, Pirsch JD, Belzer FO. Extended preservation of the liver for clinical transplantation. Lancet 1988; 1:617-619.
32. Belzer FO, D'Alessandro AM, Hoffmann RM, Knechtle SJ, Reed A, Pirsch JD, et al. The use of UW solution in clinical transplantation. A 4-year experience. Ann Surg 1992;215: 579-583.
33. Tzakis A, Todo S, Starzl TE. Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg 1989;210:649-652.
34. Neuhaus P, Blumhardt G, Bechstein WO, Steffen R, Platz KP, Keck H. Technique and results of biliary reconstruction using side-to-side choledochocholedochostomy in 300 orthotopic liver transplants. Ann Surg 1994;219:426-434.
35. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
36. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
37. Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006; 244:563-571.
38. Briceno J, Ciria R, Pleguezuelo M, Naranjo A, Sánchez-Hidalgo J, Ruiz-Rabelo J, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007;39:2297-2299.
39. Melendez HV, Heaton ND. Understanding "marginal" liver grafts. Transplantation 1999;68:469-471.
40. Trevisani F, Colantoni A, Caraceni P, Van Thiel DH. The use of donor fatty liver for liver transplantation: a challenge or a quagmire? J Hepatol 1996;24:114-121.
41. Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW Jr. Frozen section evaluation of donor livers before transplantation. Transplantation 1993;56:1403-1409.
42. Nikeghbalian S, Nejatollahi SM, Salahi H, Bahador A, Sabet B, Jalaeian H, et al. Does donor's fatty liver change impact on early mortality and outcome of liver transplantation. Transplant Proc 2007;39:1181-1183.
43. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997;64: 248-251.
44. Todo S, Demetris AJ, Makowka L, Teperman L, Podesta L, Shaver T, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989; 47:903-905.
45. D'Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991;51:157-163.
46. Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, et al. Effect of macrovesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant 2001;15:53-57.
47. Teramoto K, Bowers JL, Kruskal JB, Clouse ME. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation 1993;56:1076-1082.
48. Teramoto K, Bowers JL, Khettry U, Palombo JD, Clouse ME. A rat fatty liver transplant model. Transplantation 1993;55:737-741.
49. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003;9:500-505.
50. Salizzoni M, Franchello A, Zamboni F, Ricchiuti A, Cocchis D, Fop F, et al. Marginal grafts: finding the correct treatment for fatty livers. Transpl Int 2003;16:486-493.
51. Mangus RS, Tector AJ, Agarwal A, Vianna R, Murdock P, Fridell JA. Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantation. Liver Transpl 2006;12: 226-230.
52. Ohwada S, Sunose Y, Tsutsumi H, Iwazaki S, Aiba M, Kasahara M, et al. Celsior is superior to UW for graft preservation from non-heart-beating donors in a canine liver transplantation model. Transplant Proc 2001;33:922-923.
53. Nardo B, Beltempo P, Bertelli R, Montalti R, Vivarelli M, Urbani L, et al. Comparison of Celsior and University of Wisconsin solutions in cold preservation of liver from octogenarian donors. Transplant Proc 2004;36:523-524.
54. Pokorny H, Rasoul-Rockenschaub S, Langer F, Windhager T, Rosenstingl A, Lange R, et al. Histidine-tryptophanketoglutarate solution for organ preservation in human liver transplantation - a multi-centre observation study. Transpl Int 2004;17:256-260.
55. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-333.
56. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998;26:30.
57. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000;32:87-90.
58. Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. Transplantation 2005;79:261-268.
59. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
60. Gordon FD, Poterucha JJ, Germer J, Zein NN, Batts KP, Gross JB Jr, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997;63:1419-1423.
61. Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003;9:796-804.
62. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, et al. Cytomegaloviraemia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-726.
63. Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 2004;10:599-606.
64. Toniutto P, Fabris C, Avellini C, Minisini R, Bitetto D, Rossi E, et al. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005; 11:5944-5950.
65. Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007;27:758-763.
66. Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, Schiano TD. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006;12:1496-1503.